Promoting HPV Vaccination Among Young Adults in Texas
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
- 试验地点
- 2
- 主要终点
- Rate of human papillomavirus (HPV) vaccination initiation
研究概览
简要总结
This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.
详细描述
PRIMARY OBJECTIVES:
I. To determine the impact of addressing individual and system levels of influence on HPV vaccination initiation and completion rates.
II. To gain insight into mechanisms of the intervention's efficacy, individual differences, and implementation of the intervention using mixed methods.
OUTLINE: Participants are randomized to 1 of 6 groups.
GROUP I: Participants receive standard Centers for Disease Control and Prevention (CDC) information about HPV vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 26 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination
- •Ability to read and understand English
- •Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination
- •Access to a smart phone, tablet or computer that is connected to the internet
- •Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months
排除标准
- •Being pregnant
- •Having a life-threatening allergy to any component of the HPV vaccine
研究组 & 干预措施
Group VI (enhanced access to vaccine, written narratives)
Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
干预措施: Enhancing Accessibility to Health Care (Other)
Group VI (enhanced access to vaccine, written narratives)
Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
干预措施: Informational Intervention (Other)
Group VI (enhanced access to vaccine, written narratives)
Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
干预措施: Interview (Other)
Group VI (enhanced access to vaccine, written narratives)
Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
干预措施: Questionnaire Administration (Other)
Group V (enhanced access to vaccine, video narratives)
Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
干预措施: Enhancing Accessibility to Health Care (Other)
Group V (enhanced access to vaccine, video narratives)
Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
干预措施: Informational Intervention (Other)
Group V (enhanced access to vaccine, video narratives)
Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
干预措施: Interview (Other)
Group I (standard CDC information)
Participants receive standard CDC information about HPV vaccination.
干预措施: Informational Intervention (Other)
Group I (standard CDC information)
Participants receive standard CDC information about HPV vaccination.
干预措施: Interview (Other)
Group V (enhanced access to vaccine, video narratives)
Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
干预措施: Questionnaire Administration (Other)
Group I (standard CDC information)
Participants receive standard CDC information about HPV vaccination.
干预措施: Questionnaire Administration (Other)
Group II (video narratives)
Participants receive video narratives about HPV vaccination.
干预措施: Informational Intervention (Other)
Group II (video narratives)
Participants receive video narratives about HPV vaccination.
干预措施: Interview (Other)
Group II (video narratives)
Participants receive video narratives about HPV vaccination.
干预措施: Questionnaire Administration (Other)
Group III (written narratives)
Participants receive written narratives about HPV vaccination.
干预措施: Informational Intervention (Other)
Group III (written narratives)
Participants receive written narratives about HPV vaccination.
干预措施: Interview (Other)
Group III (written narratives)
Participants receive written narratives about HPV vaccination.
干预措施: Questionnaire Administration (Other)
Group IV (enhanced access to vaccine, CDC information)
Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
干预措施: Enhancing Accessibility to Health Care (Other)
Group IV (enhanced access to vaccine, CDC information)
Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
干预措施: Informational Intervention (Other)
Group IV (enhanced access to vaccine, CDC information)
Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
干预措施: Interview (Other)
Group IV (enhanced access to vaccine, CDC information)
Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
干预措施: Questionnaire Administration (Other)
结局指标
主要结局
Rate of human papillomavirus (HPV) vaccination initiation
时间窗: At 3 months
Rate of HPV vaccination completion
时间窗: At 9 months
次要结局
未报告次要终点